GlassScriptPhysician profile
Laura B Bonds
NPI 1295919116
$9,447.96
in general payments reported to CMS, 2019-2025
43 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $748 · 2021: $1,498 · 2022: $2,300 · 2023: $1,522 · 2024: $1,419 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,327 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,326.61 |
| Education | $160.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,626.74 | 2021-2025 | Qulipta, Ubrelvy, Synthroid |
| Lundbeck LLC | $1,354.31 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $793.52 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $760.85 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $756.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $584.34 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $564.52 | 2019-2025 | Ajovy |
| Impel Pharmaceuticals INC. | $514.58 | 2022-2023 | Trudhesa |
| Amgen INC. | $217.68 | 2020-2023 | Aimovig |
| Allergan, INC. | $198.66 | 2019-2021 | |
| Lilly USA, LLC | $196.90 | 2019-2024 | Emgality |
| Novartis Pharmaceuticals Corporation | $190.59 | 2019-2021 | |
| Impel Pharmaceuticals LLC | $166.96 | 2024-2025 | Trudhesa |
| Ucb, INC. | $163.34 | 2019-2022 | |
| Avion Pharmaceuticals | $146.16 | 2022-2023 | Dhivy |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Bonds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.